UNH · Q1 2026 Earnings

Cautious

UnitedHealth Group

Reported April 21, 2026

30-second summary

Revenue grew 2% YoY to $111.7B with adjusted EPS of $7.23 and MCR of 83.9% — a clean Q1 print well inside the 88.8% ±50bps FY band that was set just one quarter ago. Operating cash flow came in at $8.9B (1.4x net income). Management raised FY2026 adjusted EPS guidance from >$17.75 to >$18.25 (+$0.50) and GAAP EPS from >$17.10 to >$17.35 while reaffirming revenue >$439B — but simultaneously withdrew the operating earnings (>$24B), operating margin (~5.5%), MCR (88.8% ±50bps), OCR (12.8% ±50bps), and operating cash flow (>$18B) guides that were the entire point of the Q4 FY2025 framework restoration. One quarter after re-establishing operational accountability, UNH has dismantled it again, leaving EPS as the only number management will defend.

Headline numbers

EPS

Q1 FY2026

$7.23

Revenue

Q1 FY2026

$111.70B

+2.0% YoY

Free cash flow

Q1 FY2026

$8.15B

Operating margin

Q1 FY2026

8.0%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$111.70B	+2.0%	$113.20B	-1.3%
EPS	$7.23	—	$2.11	+242.7%
Operating margin	8.0%	—	0.3%	+770bps
Free cash flow	$8.15B	—	—	—

Guidance

UnitedHealth raised full-year adjusted EPS guidance from >$17.75 to >$18.25 and GAAP EPS from >$17.10 to >$17.35 while reaffirming revenue, but withdrew detailed operating metrics and added capital allocation commitments (debt targets and accelerated buybacks).

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

Metric	Period	Guide	YoY
Debt-to-Capital Ratio	FY 2026	approximately 40.0% in H2 2026	—
Share Repurchases	FY 2026	at least $2.0 billion by end of Q2 2026	—
Acquisition Impact	FY 2026	expected to close in H2 2026 and be earnings neutral to 2026	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted EPS (non-GAAP)	FY 2026	greater than $17.75	greater than $18.25	+$0.50 at low end	Raised
GAAP EPS	FY 2026	greater than $17.10	greater than $17.35	+$0.25 at low end	Raised
Operating Earnings	FY 2026	greater than $24.0 billion	Withdrawn — no replacement	—	Withdrawn
Operating Margin	FY 2026	~5.5%	Withdrawn — no replacement	—	Withdrawn
Cash Flows from Operations	FY 2026	greater than $18.0 billion	Withdrawn — no replacement	—	Withdrawn
Medical Care Ratio	FY 2026	88.8% ± 50 basis points	Withdrawn — no replacement	—	Withdrawn
Operating Cost Ratio	FY 2026	12.8% ± 50 basis points	Withdrawn — no replacement	—	Withdrawn

Reaffirmed unchanged this quarter: Revenue (greater than $439.0 billion)

Segment KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
UnitedHealthcare	$86.3B	+2.0%
Optum	$63.7B	-0.2%
Optum Health	$24.1B	-3.0%
Optum Rx	$35.7B	+2.0%
Optum Insight	$5.1B	+2.0%
UnitedHealthcare Medicare & Retirement	$42.1B	+1.0%
UnitedHealthcare Community & State	$24.1B	+4.0%
UnitedHealthcare Employer & Individual	$20.1B	+1.4%

Other KPIs

Q1 FY2026

Segment	Q1 FY2026
Medical Cost Ratio	83.9%
Operating Cost Ratio	13.8%
Net Margin	5.6%
UnitedHealthcare Adjusted Operating Margin	6.6%
Optum Adjusted Operating Margin	5.1%
UnitedHealthcare People Served	49.1 million
Optum Consumers Served	122 million
Optum Health Consumers Served	93 million

Management tone

Q1 FY2025 operational excellence → Q2 FY2025 "we've made mistakes" → Q3 FY2025 frameworks withdrawn → Q4 FY2025 frameworks restored → Q1 FY2026 frameworks withdrawn again

Two quarters ago management dismantled the cost framework, last quarter it was restored with wider bands, this quarter it has been dismantled again. The pattern is now legible: UnitedHealth will publish operational frameworks at the start of each fiscal year and pull them mid-year when the operating cost ratio or medical care ratio drifts. The Q1 OCR of 13.8% — 100bps above the prior 12.8% FY midpoint — is the operational evidence behind this quarter's withdrawal; the EPS raise is the offsetting message designed to reframe the print as positive. The signal is that EPS has become the only metric management will commit to publicly; everything upstream of it is now optional disclosure.

The second shift is the substitution of capital allocation commitments for operational ones. Three quarters ago (Q3 FY2025) management deferred margin questions to 2026; two quarters ago (Q4 FY2025) it issued a full operational framework; this quarter it has withdrawn that framework while introducing a debt-to-capital target (~40% by H2), a buyback commitment (≥$2B by end of Q2), and an acquisition disclosure framed as "earnings neutral to 2026." The substitution is intentional — when management can't (or won't) defend the margin frame, it shifts the narrative to balance-sheet discipline and capital return. The "earnings neutral" acquisition qualifier in particular is a tell: it pre-commits investors not to expect accretion, which is unusual language for a deal management is announcing as part of its forward strategy.

The third shift is in the Q&A's center of gravity. In Q4 FY2025 the dominant analyst question was MA membership decline; this quarter it has rotated to medical cost trend granularity (Rice asking whether MA trend is running 7-8% or 10%) and Optum Health beat quality (Lake asking whether $1.3B is comparable to the $1.575B guidance midpoint). Management's answers have hardened — Krista's disclosure of 35% reduction in SNF admissions in the West region and 12% YoY increase in patient-facing hours is the most specific Optum Health operational data point in three quarters of coverage — but the caution remains. Krista's "cautious on extrapolating given only one quarter maturity" on PYD favorability is the line that captures management's current posture: deliver the EPS, qualify everything else.

Q&A highlights

AJ Rice · UBS

Clarification on Medicare Advantage medical cost trend: Is it running closer to 10% (pricing assumption) or 7-8% (historical), and where is any acceleration or moderation occurring?

Tim Grayson confirmed trend is progressing in line with expectations across UnitedHealthcare. Seeing modest favorability in government programs including Medicare Advantage, with no inflection point. Utilization patterns remain elevated consistent with 2025 levels. Comfortable with 2026 pricing posture given early performance.

7-8% historical trend in Medicare Advantage~10% pricing assumption for 2026Modest favorability in government programsElevated utilization patterns consistent with 2025

Kevin Fishbeck · Bank of America

Can you size the acuity and provider billing component of trend and explain what actions can address it? Is this an MA-only issue or broader across all products?

Tim confirmed this is a theme across all products, not just MA. Management is using better tools to identify outlier patterns early, engaging clinical programs, leveraging payment integrity programs, and taking network actions where appropriate. HMO-based product positioning in MA to better manage outlier activity. Promised more detail in Q2.

Acuity trend issue across all productsEarly identification tools for outlier patternsNetwork actions taken to address outliersHMO-based product positioning in MA

Andrew Mock · Barclays

What is driving Optum Health outperformance: pricing/contracts versus utilization? And what explains why earnings are concentrated in first half despite being a risk business?

Krista confirmed two drivers: (1) favorable medical cost restating from prior periods, concentrated in markets with focused clinical management (e.g., West region with 35% reduction in SNF admissions), and (2) operating performance improvements including 12% YoY increase in patient-facing hours. Optum Health now resembles risk business seasonality with majority earnings in first half.

West region SNF admissions down ~35% MoM vs. prior yearClinical reviews increased 50%+ in focus markets12% YoY increase in patient-facing hoursMajority of OptumHealth earnings in first half due to risk business seasonality

Justin Lake · Wolf Research

Is $1.3B OptumHealth adjusted earnings comparable to $1.575B guidance? How much of the beat versus internal expectations comes from PYD versus run rate improvement?

Wayne confirmed $1.3B is the clean comparable to $1.575B guidance, removing non-cash accounting on lost contract and asset dispositions. All four segments exceeded internal plan. Krista noted PYD favorable but performance aligns with intentional Q4 actions taken; cautious on extrapolating given only one quarter maturity.

$1.3B adjusted earnings vs. $1.575B original guidanceAll segments exceeded internal planPrior period development favorable but expected given Q4 restructuring actionsCautious stance on sustainability given single quarter of data

Stephen Baxter · Wells Fargo

Given final Medicare rate notice, what is your confidence in margin recovery for 2027? And will you participate in CMS GLP-1 balance program, and will thresholds be met?

Bobby acknowledged final notice improved funding but trend still meaningfully above funding levels. 2026 targeting 50bps margin advance YoY; 2027 aspiration upper half of 2-4% long-term range. On GLP-1 balance program: active dialogue with CMS/CMMI seeking path to yes, but notable challenges and outstanding questions in structure. Participating in bridge demo starting July.

2026 target: 50bps margin advance YoY2027 aspiration: upper half of 2-4% long-term margin rangeFinal rate notice improved funding but below 2027 trend expectationsGLP-1 balance program: active negotiations, bridge demo July

Answers to last quarter's watch list

Q1 FY2026 MCR vs the 88.8% ±50bps band. Q1 FY2026 MCR came in at 83.9%, ~490bps below the FY midpoint and well within the seasonal pattern management described. The metric performed as designed — but management has now withdrawn the band entirely, so the question of whether the framework holds for the full year cannot be answered from this print.

Not resolved

Operating cash flow trajectory vs the >$18B FY2026 guide. Q1 operating cash flow came in at $8.9B (1.4x net income), a strong figure that on a straight-line basis would imply substantially more than $18B for the year. But the >$18B OCF guide has been withdrawn alongside operating margin and MCR, so the implied conversion ratio that was the focus last quarter is no longer the reference point.

Not resolved

MA membership at AEP close. Medicare & Retirement revenue grew just +1% YoY in Q1 vs +27.5% in Q4 FY2025, and Tim Noel guided to a full-year MA membership decline centering around 1.3M. The UHC adjusted operating margin of 6.6% suggests the smaller base is starting to deliver the targeted margin recovery, though one quarter is insufficient to confirm the 50bps annual improvement target.

Continue monitoring

2027 CMS final rate notice and management's response. Bobby confirmed 2026 targets ~50bps margin advance and 2027 aspires to the upper half of the 2-4% range, with final rate funding still below 2027 trend expectations. Management did not quantify a 2027 EPS bridge, deferring specificity. The 2027 path remains ambitious and unquantified.

Continue monitoring

Optum Health Q1 FY2026 revenue trajectory and recast baseline. Revenue declined 3% YoY, accelerating from -0.5% in Q4 FY2025 — the third consecutive quarter of decline. However, Krista disclosed Optum Health Q1 adjusted earnings of $1.3B (vs the $1.575B FY2026 quarterly guidance midpoint and the recast $1.45B FY2025 full-year base), with the West region SNF admissions down ~35% and patient-facing hours +12% YoY. The leaner book appears more profitable per patient, but management is explicitly cautious on extrapolating one quarter.

Continue monitoring

What to watch into next quarter

Whether the operating margin, MCR, OCR, and OCF guidance frameworks are re-issued at the Q2 FY2026 print or remain withdrawn. This will be the third instance of the cycle (withdraw Q3 FY2025 → restore Q4 FY2025 → withdraw Q1 FY2026). A second consecutive withdrawal hardens the read that UNH has structurally moved to an EPS-only disclosure framework.

Q2 FY2026 OCR specifically — does it move below 13.8% or stay elevated? The Q1 OCR running 100bps above the prior FY midpoint is the most plausible source of pressure on the withdrawn frame. A Q2 print at or above 13.8% would suggest the cost framework was pulled because it was failing, not because management chose simplicity.

Optum Health Q2 FY2026 revenue — does the -3% Q1 decline narrow toward zero or widen further? With operating earnings concentrated in the first half (per Krista's risk-business seasonality framing), Q2 is the last quarter where the FY2026 >$2.2B operating earnings target can build a meaningful cushion before the harder back half. A Q2 revenue print worse than -3% strains the +52% YoY recovery on the recast base.

Sizing of the acuity component disclosed in Q2. Tim Noel committed to providing more detail in Q2 on the acuity/provider-billing component of trend. Whether management quantifies this — and whether the size is consistent with the 2027 margin recovery to the upper half of 2-4% — is the most important forward disclosure.

CMS GLP-1 bridge demo signal post-July start. UNH is participating in the bridge demo starting July; any disclosure of expected economics, threshold structure, or whether the program meets UNH's pre-conditions would materially de-risk (or rule out) GLP-1 as a 2027+ cost or revenue lever.

Sources

UnitedHealth Group Q1 FY2026 Press Release / Form 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/731766/000073176626000121/uhgearningsreleaseq12026.htm
UnitedHealth Group Q1 FY2026 earnings call Q&A — Tim Noel, Krista, Wayne, Bobby, Patrick; AJ Rice (UBS), Kevin Fishbeck (Bank of America), Andrew Mock (Barclays), Justin Lake (Wolfe Research), Stephen Baxter (Wells Fargo), Lisa Gill (J.P. Morgan)
Tapebrief UNH Q4 FY2025, Q3 FY2025, and Q2 FY2025 briefs (prior coverage)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.